TY - JOUR
TI - COVID-19 and Thrombotic or Thromboembolic Disease: Implications for
Prevention, Antithrombotic Therapy, and Follow
AU - Bikdeli, Behnood
AU - Madhavan, Mahesh V.
AU - Jimenez, David
AU - Chuich,
AU - Taylor
AU - Dreyfus, Isaac
AU - Driggin, Elissa
AU - Der Nigoghossian,
AU - Caroline
AU - Ageno, Walter
AU - Madjid, Mohammad
AU - Guo, Yutao
AU - Tang,
AU - Liang V.
AU - Hu, Yu
AU - Giri, Jay
AU - Cushman, Mary
AU - Quere, Isabelle
AU - and Dimakakos, Evangelos P.
AU - Gibson, C. Michael
AU - Lippi, Giuseppe
AU - and Favaloro, Emmanuel J.
AU - Fareed, Jawed
AU - Caprini, Joseph A. and
AU - Tafur, Alfonso J.
AU - Burton, John R.
AU - Francese, Dominic P.
AU - Wang,
AU - Elizabeth Y.
AU - Falanga, Anna
AU - McLintock, Claire
AU - Hunt, Beverley
AU - J.
AU - Spyropoulos, Alex C.
AU - Barnes, Geoffrey D.
AU - Eikelboom, John
AU - W.
AU - Weinberg, Ido
AU - Schulman, Sam
AU - Carrier, Marc
AU - Piazza,
AU - Gregory
AU - Beckman, Joshua A.
AU - Steg, Gabriel
AU - Stone, Gregg W. and
AU - Rosenkranz, Stephan
AU - Goldhaber, Samuel Z.
AU - Parikh, Sahil A. and
AU - Monreal, Manuel
AU - Krumholz, Harlan M.
AU - Konstantinides, Stavros V.
AU - and Weitz, Jeffrey I.
AU - Lip, Gregory Y. H.
AU - Global COVID-19
AU - Thrombosis Collabo
AU - ISTH
AU - NATF
AU - ESVM
AU - ESC Working Grp Pulm
AU - Ci
JO - Journal of the American College of Cardiology
PY - 2020
VL - 75
TODO - 23
SP - 2950-2973
PB - EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
SN - 0735-1097, 1558-3597
TODO - 10.1016/j.jacc.2020.04.031
TODO - null
TODO - Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused
by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may
predispose patients to thrombotic disease, both in the venous and
arterial circulations, because of excessive inflammation, platelet
activation, endothelial dysfunction, and stasis. In addition, many
patients receiving antithrombotic therapy for thrombotic disease may
develop COVID-19, which can have implications for choice, dosing, and
laboratory monitoring of antithrombotic therapy. Moreover, during a time
with much focus on COVID-19, it is critical to consider how to optimize
the available technology to care for patients without COVID-19 who have
thrombotic disease. Herein, the authors review the current understanding
of the pathogenesis, epidemiology, management, and outcomes of patients
with COVID-19 who develop venous or arterial thrombosis, of those with
pre-existing thrombotic disease who develop COVID-19, or those who need
prevention or care for their thrombotic disease during the COVID-19
pandemic. (J Am Coll Cardiol 2020;75:2950-73) (c) 2020 by the American
College of Cardiology Foundation.
ER -